Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
astatine-211-labelled trastuzumab (also known as 211At-trastuzumab) is a clinical-stage targeted alpha therapy (TAT) radiopharmaceutical. It consists of the humanized anti-HER2 monoclonal antibody trastuzumab radiolabeled with the alpha-emitting radionuclide astatine-211 ($^{211}\text{At}$). The drug is designed to selectively target and destroy human epidermal growth factor receptor 2 (HER2)-expressing cancer cells. Upon binding to HER2, the high linear energy transfer (LET) alpha particles emitted by the decay of astatine-211 induce localized, irreparable double-strand DNA breaks in the tumor cells, minimizing damage to surrounding healthy tissues. It is primarily being developed for the intraperitoneal treatment of disseminated HER2-positive cancers, such as ovarian cancer, and has also been investigated preclinically for gastric cancer and uterine serous carcinoma.
| Indication | Highest phase | Status |
|---|---|---|
| gastric cancer and precursor lesions | Preclinical | Active |
| ovarian cancer and premalignant lesions | In development | Active |
| serous endometrial carcinoma | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Patent families, expiry dates and exclusivities are in the full profile.
Lead indication: gastric cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on astatine-211-labelled trastuzumab.
Work on astatine-211-labelled trastuzumab? Claim this page to correct or add information. Claim this page